Its new test that will detect two types of SARS-CoV-2 antibodies will run on an open instrument platform.
News & Analysis: Thermo Fisher Scientific
TMO earnings call for the period ending March 28, 2020.
The healthcare giant's COVID-19 efforts are helping it weather the storm.
These are stocks you can own and forget about.
The agency hasn't approved any in-home test kits yet.
Disruptions in clinical trials and delayed regulatory decisions could slow the rate of new drug approvals.
But Mayor Bill de Blasio does have emergency powers he can invoke that are short of a full lockdown.
There's no shortage yet, but the FDA is working to address supply issues with a key component of COVID-19 diagnostics tests.
The world's leading manufacturer of scientific tools aims to rapidly address the shortage of coronavirus diagnostic kits in the U.S.
The diagnostic-test maker is being acquired for $11.5 billion.